Premium
CD 8+ tumour‐infiltrating lymphocytes in relation to HPV status and clinical outcome in patients with head and neck cancer after postoperative chemoradiotherapy: A multicentre study of the G erman cancer consortium radiation oncology group ( DKTK ‐ ROG )
Author(s) -
Balermpas Panagiotis,
Rödel Franz,
Rödel Claus,
Krause Mechthild,
Linge Annett,
Lohaus Fabian,
Baumann Michael,
Tinhofer Inge,
Budach Volker,
Gkika Eleni,
Stuschke Martin,
Avlar Melanie,
Grosu AncaLidia,
Abdollahi Amir,
Debus Jürgen,
Bayer Christine,
Stangl Stefan,
Belka Claus,
Pigorsch Steffi,
Multhoff Gabriele,
Combs Stephanie E.,
Mönnich David,
Zips Daniel,
Fokas Emmanouil
Publication year - 2015
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.29683
Subject(s) - medicine , chemoradiotherapy , oncology , head and neck cancer , radiation therapy , tumor infiltrating lymphocytes , cd8 , cancer , biomarker , cisplatin , multivariate analysis , pathology , chemotherapy , immunotherapy , immune system , immunology , biology , biochemistry
We examined the prognostic value of tumour‐infiltrating lymphocytes (TILs) in patients with squamous cell carcinoma of the head and neck (SCCHN) after surgery and postoperative cisplatin‐based chemoradiotherapy. FFPE‐tissue originating from the surgery of 161 patients treated in 8 DKTK partner sites was immunohistochemically stained for CD3 and CD8. Their expression was correlated with clinicopathological characteristics as well as overall survival (OS), local progression‐free survival (LPFS) and distant metastases free‐survival (DMFS), also in the context of the HPV16‐DNA/p16 status. After a median follow‐up of 48 months (range: 4100 months), OS at 4 years was 46.5% for the entire cohort. In multivariate analysis, high CD8 expression was confirmed as an independent prognostic parameter for OS ( p = 0.002), LPFS ( p = 0.004) and DMFS ( p = 0.006), while CD3 expression lacked significance. In multivariate analysis HPV16 DNA positivity was associated with improved OS ( p = 0.025) and LPFS ( p = 0.013) and p 16‐positive patients showed improved DMFS ( p = 0.008). Interestingly, high CD8 expression was a prognostic parameter for the clinical outcome in both HPV16 DNA‐positive and HPV16 DNA‐negative patients. Similar findings were observed in the multivariate analysis for the combined HPV16 DNA/p16 status. Altogether, CD8+ TILs constitute an independent prognostic marker in SCCHN patients treated with adjuvant chemoradiotherapy. These data indicate that CD8‐positive TILs have antitumour activity and could be used for treatment stratification. Further validation of the prognostic value of CD8+ TILs as a biomarker and its role in the immune response in SCCHN patients after adjuvant chemoradiotherapy is warranted and will be performed in the prospective DKTK‐ROG study.